News Ticker

Mel Gibson & Dr. Neil Riordan STEM CELLS

January 17, 2018 Yegor Khzokhlachev Aging, Disease, Future, Health, Science, Technology 0

Will Sasso’s Monster Calves

September 30, 2023 Yegor Khzokhlachev Lee Haney 0

Will Sasso: Calf King How often, throughout the course of your existence, have you encountered individuals who, by all appearances, abstain from the rigors of physical exertion, yet manifest calf musculature akin to that of […]

Rare Sergio Oliva Photos: Part 2

September 30, 2023 Yegor Khzokhlachev Lee Haney 0

Arnold from the Encyclopedia of Modern Bodybuilding No one is immune to being psyched out. I have to admit that I’ve been on the receiving end of this treatment as well as dishing it out. […]

Rare Arnold Schwarzenegger Photos: Part 4

September 30, 2023 Yegor Khzokhlachev Lee Haney 0

Bill Dobbins on Arnold Joe Weider and Arnold had a mutual respect with a certain degree of conflict. That is, Arnold was the only bodybuilder who really knew how to handle Joe Weider. Joe would […]

Mel Gibson & Dr. Neil Riordan discuss stem cells on Joe Rogan

Neil Riordan, PA, PhD is one of the early pioneers and experts in applied stem cell research. Dr. Riordan founded publicly traded company Medistem Laboratories (later Medistem Inc.) which was acquired by Intrexon in 2013.

He is the founder and chairman of Medistem Panama, Inc., a leading stem cell laboratory and research facility located in the Technology Park of the prestigious City of Knowledge in Panama City, Panama. Medistem Panama (est. 2007) is at the forefront of research on the effects of adult stem cells on the course of several chronic diseases and conditions. The stem cell laboratory at Medistem Panama is fully licensed by the Ministry of Health of Panama.

Human umbilical cord tissue-derived mesenchymal stem cells (hUCT-MSCs) that were isolated and grown at Medistem Panama to create master cell banks are currently being used in the United States. These cells serve as the starting material for cellular products used in MSC clinical trials for two Duchenne’s muscular dystrophy patients under US FDA’s designation of Investigational New Drug (IND) for single patient compassionate use. (IND 16026 DMD Single Patient) These trials are the first in the United States to use hUCT-MSCs. Translational Biosciences, a fully-owned subsidiary of Medistem Panama is currently conducting phase I/II clinical trials for multiple sclerosis, autism and rheumatoid arthritis.

Riordan-McKenna Institute